Inhibiting low-density lipoprotein glycation ameliorates increased cholesteryl ester synthesis in macrophages and hypercholesterolemia and aortic lipid peroxidation in streptozotocin diabetic rats.

Metabolism: Clinical and Experimental
M P CohenVan-Yu Wu

Abstract

Increased nonenzymatic glycation of apolipoprotein (apo) B-containing lipoproteins impairs uptake and metabolism by the high-affinity low-density lipoprotein receptor and is one of the postsecretory modifications contributory to accelerated atherosclerosis in diabetes. The present study evaluated in vitro and in vivo effects of 2,2-chlorophenylaminophenylacetate to probe the influence of glycated lipoprotein on cholesterol homeostasis. This compound prevented the increased formation of glycated products in low-density lipoprotein incubated with 200 mmol/L glucose and the increased cholesteryl ester synthesis in THP-1 macrophages induced by apo B-containing lipoproteins preincubated with high glucose concentration. The elevated circulating concentrations of glycated lipoprotein and cholesterol and higher vascular levels of lipid peroxidation products observed in streptozotocin diabetic rats compared with nondiabetic controls were significantly reduced in diabetic animals treated for 6 months with test compound. These results are the first to demonstrate that inhibiting nonenzymatic glycation of apo B-containing lipoproteins ameliorates abnormalities contributory to hypercholesterolemia and atherogenic risk in diabetes.

References

Sep 1, 1990·Journal of Medicinal Chemistry·P MoserI Wiesenberg
Mar 1, 1990·Chemical Research in Toxicology·H EsterbauerG Jürgens
Dec 31, 1990·Biochemical and Biophysical Research Communications·C J MullarkeyM Brownlee
Feb 8, 1990·Nature·M S Brown, J L Goldstein
May 15, 1985·Biochemical Pharmacology·J M ChamouardJ P Tillement
Jan 1, 1984·Methods in Enzymology·R Flückiger, P M Gallop
Nov 1, 1993·European Journal of Clinical Chemistry and Clinical Biochemistry : Journal of the Forum of European Clinical Chemistry Societies·M P CohenE Shea
Aug 14, 1998·Free Radical Research·S A MillicanJ V Hunt
Sep 7, 1999·Diabetic Medicine : a Journal of the British Diabetic Association·E MoroG B Bon
Dec 2, 1999·Diabetes Research and Clinical Practice·I J EdwardsW T Cefalu
Aug 18, 2001·Journal of Applied Physiology·V VelardeA A Jaffa
Jun 22, 2002·Metabolism: Clinical and Experimental·Margo P CohenClyde W Shearman
Jun 17, 2004·Diabetes Technology & Therapeutics·Margo P CohenGregory T Lautenslager
Dec 16, 2006·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·G MisciagnaM Trevisan
Sep 21, 2007·Journal of Cellular Biochemistry·Melinda E WilsonKimberly F Allred
Jul 9, 2008·Current Opinion in Lipidology·Nahla YounisPaul N Durrington

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.